5-ASAs Combined With a Biologic or Tofacitinib: Predetermined Cost-Effectiveness?

Am J Gastroenterol. 2021 Sep 1;116(9):1958-1959. doi: 10.14309/ajg.0000000000001296.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Biological Products*
  • Cost-Benefit Analysis
  • Humans
  • Piperidines
  • Pyrimidines*
  • Pyrroles

Substances

  • Biological Products
  • Piperidines
  • Pyrimidines
  • Pyrroles
  • tofacitinib